Senti Biosciences

Senti Biosciences (Senti Bio) is a clinical-stage biotechnology company developing cell and gene therapies for patients with incurable diseases. Its approach centers on a synthetic biology platform used to engineer "Gene Circuits" into therapeutic candidates. According to the company, these circuits are designed to kill cancer cells precisely while sparing healthy cells, increase specificity to target tissues, and remain controllable after administration.

The company's wholly owned pipeline consists of cell therapies engineered with Gene Circuits aimed at difficult-to-treat liquid and solid tumors. Senti Bio states that its Gene Circuits have been shown to function both clinically and preclinically and in both NK and T cells, allowing selection of the cell type suited to each indication. The lead product candidate, SENTI-202, is being evaluated in a global clinical trial in acute myeloid leukemia (AML), where the company reports positive preliminary efficacy data. Beyond oncology, Senti Bio says it has demonstrated the potential of Gene Circuits in other modalities and diseases preclinically and continues to advance those capabilities through partnerships.

Business model

Senti Bio advances a wholly owned pipeline of engineered cell therapy candidates and additionally applies its Gene Circuit platform to non-oncology modalities and diseases through partnerships.

Traction

Lead candidate SENTI-202 is in a global clinical trial for acute myeloid leukemia and, per the company, has generated positive preliminary efficacy data. Gene Circuits are reported to have worked both clinically and preclinically.